SINGULAR GENOMICS SYSTEMS IN (OMIC) Fundamental Analysis & Valuation
NASDAQ:OMIC • US82933R3084
Current stock price
20.01 USD
+0.05 (+0.25%)
Last:
This OMIC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. OMIC Profitability Analysis
1.1 Basic Checks
- OMIC had negative earnings in the past year.
- OMIC had a negative operating cash flow in the past year.
- OMIC had negative earnings in each of the past 5 years.
- In the past 5 years OMIC always reported negative operating cash flow.
1.2 Ratios
- OMIC has a worse Return On Assets (-46.27%) than 87.50% of its industry peers.
- OMIC's Return On Equity of -70.04% is on the low side compared to the rest of the industry. OMIC is outperformed by 73.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.27% | ||
| ROE | -70.04% | ||
| ROIC | N/A |
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- OMIC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. OMIC Health Analysis
2.1 Basic Checks
- OMIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for OMIC has been reduced compared to 1 year ago.
- The debt/assets ratio for OMIC is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -3.44, we must say that OMIC is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -3.44, OMIC is doing worse than 85.71% of the companies in the same industry.
- A Debt/Equity ratio of 0.04 indicates that OMIC is not too dependend on debt financing.
- With a decent Debt to Equity ratio value of 0.04, OMIC is doing good in the industry, outperforming 69.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.44 |
ROIC/WACCN/A
WACC11.59%
2.3 Liquidity
- A Current Ratio of 7.37 indicates that OMIC has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 7.37, OMIC belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
- A Quick Ratio of 6.67 indicates that OMIC has no problem at all paying its short term obligations.
- The Quick ratio of OMIC (6.67) is better than 83.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.37 | ||
| Quick Ratio | 6.67 |
3. OMIC Growth Analysis
3.1 Past
- OMIC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.62%, which is quite good.
- Looking at the last year, OMIC shows a small growth in Revenue. The Revenue has grown by 2.54% in the last year.
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%
3.2 Future
- Based on estimates for the next years, OMIC will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.54% on average per year.
- OMIC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 108.68% yearly.
EPS Next Y11.81%
EPS Next 2Y8.6%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue Next Year9.93%
Revenue Next 2Y96.89%
Revenue Next 3Y108.68%
Revenue Next 5YN/A
3.3 Evolution
4. OMIC Valuation Analysis
4.1 Price/Earnings Ratio
- OMIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMIC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.6%
EPS Next 3Y9.54%
5. OMIC Dividend Analysis
5.1 Amount
- No dividends for OMIC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OMIC Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:OMIC (2/20/2025, 8:00:01 PM)
20.01
+0.05 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-17 2025-03-17/amc
Inst Owners54.77%
Inst Owner Change-72.02%
Ins Owners14.13%
Ins Owner Change0%
Market Cap50.63M
Revenue(TTM)2.67M
Net Income(TTM)-86.32M
Analysts80
Price Target12.7 (-36.53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.66%
Min EPS beat(2)5.17%
Max EPS beat(2)18.16%
EPS beat(4)4
Avg EPS beat(4)9.18%
Min EPS beat(4)4.76%
Max EPS beat(4)18.16%
EPS beat(8)8
Avg EPS beat(8)13.23%
EPS beat(12)12
Avg EPS beat(12)13.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)14.44%
Min Revenue beat(2)-51.75%
Max Revenue beat(2)80.64%
Revenue beat(4)3
Avg Revenue beat(4)20.95%
Min Revenue beat(4)-51.75%
Max Revenue beat(4)80.64%
Revenue beat(8)3
Avg Revenue beat(8)-8.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.5%
EPS NY rev (1m)0.83%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 18.99 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.41 | ||
| P/tB | 0.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-35.09
EYN/A
EPS(NY)-32.25
Fwd EYN/A
FCF(TTM)-31.96
FCFYN/A
OCF(TTM)-31.79
OCFYN/A
SpS1.05
BVpS48.72
TBVpS48.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.27% | ||
| ROE | -70.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.24% | ||
| Cap/Sales | 15.87% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.37 | ||
| Quick Ratio | 6.67 | ||
| Altman-Z | -3.44 |
F-Score3
WACC11.59%
ROIC/WACCN/A
Cap/Depr(3y)235.15%
Cap/Depr(5y)229.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
EPS Next Y11.81%
EPS Next 2Y8.6%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%
Revenue Next Year9.93%
Revenue Next 2Y96.89%
Revenue Next 3Y108.68%
Revenue Next 5YN/A
EBIT growth 1Y5.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.13%
EBIT Next 3Y3.57%
EBIT Next 5YN/A
FCF growth 1Y9.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.96%
OCF growth 3YN/A
OCF growth 5YN/A
SINGULAR GENOMICS SYSTEMS IN / OMIC Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SINGULAR GENOMICS SYSTEMS IN (OMIC) stock?
ChartMill assigns a fundamental rating of 2 / 10 to OMIC.
What is the valuation status for OMIC stock?
ChartMill assigns a valuation rating of 0 / 10 to SINGULAR GENOMICS SYSTEMS IN (OMIC). This can be considered as Overvalued.
How profitable is SINGULAR GENOMICS SYSTEMS IN (OMIC) stock?
SINGULAR GENOMICS SYSTEMS IN (OMIC) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for OMIC stock?
The Earnings per Share (EPS) of SINGULAR GENOMICS SYSTEMS IN (OMIC) is expected to grow by 11.81% in the next year.